TY - JOUR
T1 - Controlled release of 18-β-Glycyrrhetic Acid by nanodelivery systems increases Cytotoxicity On Oral Carcinoma Cell Line.
AU - Cacciotti, Ilaria
AU - Chronopoulou, Laura
AU - Palocci, Cleofe
AU - Amalfitano, Adriana
AU - Cantiani, Monica
AU - Cordaro, Massimo
AU - Lajolo, Carlo
AU - Calla', Cinzia Anna Maria
AU - Boninsegna Lucarelli, Alma
AU - Lucchetti, Donatella
AU - Gallenzi, Patrizia
AU - Sgambato, Alessandro
AU - Nocca, Giuseppina
AU - Arcovito, Alessandro
PY - 2018
Y1 - 2018
N2 - The topical treatment for oral mucosal diseases is often based on products optimized for dermatologic applications; consequently, a lower therapeutic effect may be present.
18-β-Glycyrrhetic Acid (GA) is extracted from Glycirrhiza glabra. The first aim of this study was to test the cytotoxicity of GA on PE/CA-PJ15 cells. The second aim was to propose and test two different delivery systems, i.e. nanoparticles and fibers, to guarantee a controlled release of GA in vitro. We used chitosan and poly(lactic-co-glycolic) acid based nanoparticles and polylactic acid fibers. We tested both delivery systems in vitro on PE/CA-PJ15 cells and on normal human gingival fibroblasts (HGFs).
The morphology of GA-loaded nanoparticles (GA-NPs) and fibers (GA-FBs) was investigated by electron microscopy and dynamic light scattering; GA release kinetics was studied spectrophotometrically. MTT test was used to assess GA cytotoxicity on both cancer and normal cells. Cells were exposed to different concentrations of GA (20 - 500 µmol/L) administered as free GA (GA-f), and to GA-NPs or GA-FBs. ROS production was evaluated using dichlorodihydrofluorescein as a fluorescent probe.
Regarding the cytotoxic effect of GA on PE/CA-PJ15 cells, the lowest TC50 value was 200 µmol/L when GA was added as GA-NPs. No cytotoxic effects were observed when GA was administered to HGFs. N-acetyl Cysteine reduced mortality induced by GA-f in PE/CA-PJ15 cells.
The specific effect of GA on PE/CA-PJ15 cells is mainly due to the different sensitivity of cancer cells to ROS over-production; GA-NPs and GA-FBs formulations increase, in vitro, this toxic effect on oral cancer cells.
AB - The topical treatment for oral mucosal diseases is often based on products optimized for dermatologic applications; consequently, a lower therapeutic effect may be present.
18-β-Glycyrrhetic Acid (GA) is extracted from Glycirrhiza glabra. The first aim of this study was to test the cytotoxicity of GA on PE/CA-PJ15 cells. The second aim was to propose and test two different delivery systems, i.e. nanoparticles and fibers, to guarantee a controlled release of GA in vitro. We used chitosan and poly(lactic-co-glycolic) acid based nanoparticles and polylactic acid fibers. We tested both delivery systems in vitro on PE/CA-PJ15 cells and on normal human gingival fibroblasts (HGFs).
The morphology of GA-loaded nanoparticles (GA-NPs) and fibers (GA-FBs) was investigated by electron microscopy and dynamic light scattering; GA release kinetics was studied spectrophotometrically. MTT test was used to assess GA cytotoxicity on both cancer and normal cells. Cells were exposed to different concentrations of GA (20 - 500 µmol/L) administered as free GA (GA-f), and to GA-NPs or GA-FBs. ROS production was evaluated using dichlorodihydrofluorescein as a fluorescent probe.
Regarding the cytotoxic effect of GA on PE/CA-PJ15 cells, the lowest TC50 value was 200 µmol/L when GA was added as GA-NPs. No cytotoxic effects were observed when GA was administered to HGFs. N-acetyl Cysteine reduced mortality induced by GA-f in PE/CA-PJ15 cells.
The specific effect of GA on PE/CA-PJ15 cells is mainly due to the different sensitivity of cancer cells to ROS over-production; GA-NPs and GA-FBs formulations increase, in vitro, this toxic effect on oral cancer cells.
KW - 18-β-Glycyrrhetic Acid
KW - Oral cavity pathologies.
KW - PLA nanofibers
KW - PLGA nanoparticles
KW - ROS production
KW - molecular targeted therapies
KW - targeted drug
KW - 18-β-Glycyrrhetic Acid
KW - Oral cavity pathologies.
KW - PLA nanofibers
KW - PLGA nanoparticles
KW - ROS production
KW - molecular targeted therapies
KW - targeted drug
UR - http://hdl.handle.net/10807/119064
UR - http://iopscience.iop.org/article/10.1088/1361-6528/aabecc/pdf
U2 - 10.1088/1361-6528/aabecc
DO - 10.1088/1361-6528/aabecc
M3 - Article
SN - 0957-4484
VL - 29
SP - 1
EP - 29
JO - Nanotechnology
JF - Nanotechnology
ER -